Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998125 | 1.00 | ANPEP (0.57) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL6951241 | 1.00 | ANPEP (0.57) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL2943529 | 1.00 | ANPEP (0.57) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Ammonia Solution, Strong SCHEMBL6107709 | 0.98 | ANPEP (0.55) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Water SCHEMBL22090286 | 0.98 | ANPEP (0.55) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Iodide SCHEMBL10818108 | 0.96 | ANPEP (0.53) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Sulfurous Acid SCHEMBL10813687 | 0.88 | ANPEP (0.47) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL885265 | 0.87 | ANPEP (0.52) | ANPEPPLAUMTNR1AMTNR1BHTR1A | |
| SCHEMBL13482664 | 0.86 | TSHR (0.50) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Vinyl Ether SCHEMBL27610276 | 0.85 | ANPEP (0.45) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111393258-B | Method for synthesizing tetrahydronaphthalene-2-alcohol derivative compound | 浙江工业大学 | 2022-08-23 | — | — | CN | claimed |
| EP-3883932-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | New York University (US) | 2021-09-29 | — | — | EP | claimed |
| CN-111393258-A | Method for synthesizing tetrahydronaphthalene-2-alcohol derivative compound | 浙江工业大学 | 2020-07-10 | — | — | CN | claimed |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CAVION, INC. (US) | 2020-06-25 | — | — | US | claimed |
| US-20200163943-A1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION, INC. (US) | 2020-05-28 | — | — | US | claimed |
| EP-3615010-A1 | METHODS FOR TREATING DRAVET SYNDROME | Cavion, Inc. (US) | 2020-03-04 | — | — | EP | claimed |
| EP-3615521-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | Cavion, Inc. (US) | 2020-03-04 | — | — | EP | claimed |
| CN-110628475-A | Process for pretreating rich gas in refinery and process for desulfurizing dry gas and/or liquefied gas | 中国石油化工股份有限公司 | 2019-12-31 | — | — | CN | claimed |
| WO-2018200850-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CAVION, INC. (US) | 2018-11-01 | — | — | WO | claimed |
| WO-2018200844-A1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION, INC. (US) | 2018-11-01 | — | — | WO | claimed |
| US-5427710-A | Containing conjugated terpene, benzyl alcohol or derivative, organoclay rheological additive, optionally surfactant, additional terpene; biodegradable, nonflammable | STEVENS EDWIN (US) | 1995-06-27 | — | — | US | claimed |
| US-5425893-A | Remover consists of conjugated terpene and terpene compounds, benzyl alcohol, surfactants, chlorophyll and organoclay thixotropic agents; nontoxic, and biodegradable | STEVENS EDWIN (US) | 1995-06-20 | — | — | US | claimed |
| WO-1995015322-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 4-HYDROXYCOUMARINS | GREAT LAKES FINE CHEMICALS LIMITED (GB) | 1995-06-08 | — | — | WO | claimed |
| EP-0648201-A1 | Enantioselective hydrogenation of the carbonyl bond using ruthenium complexes with biphosphine ligands. | ELF AQUITAINE (FR) | 1995-04-19 | — | — | EP | claimed |
| WO-1994024216-A1 | PAINT STRIPPING COMPOSITIONS AND METHODS | STEVENS EDWIN (US) | 1994-10-27 | — | — | WO | claimed |
| WO-1994001390-A1 | ENANTIOSELECTIVE CARBONYL GROUP HYDROGENATION METHOD USING RUTHENIUM/DIPHOSPHINE LIGAND COMPLEXES | ELF AQUITAINE (FR) | 1994-01-20 | — | — | WO | claimed |
| EP-0338311-B1 | Oil composition containing hydrogenated oil | NIPPON OIL CO LTD (JP) | 1993-12-15 | — | — | EP | claimed |
| EP-0469683-A1 | Derivatives of 4-amino-1-methyltetralins, their preparation and their application in therapy | LABORATOIRES LUCIEN, Société Anonyme : (FR) | 1992-02-05 | — | — | EP | claimed |
| US-4473711-A | CHROMIUM(III) ION EXCHANGED RESIN CATALYST | UNION CARBIDE CORPORATION (US) | 1984-09-25 | — | — | US | claimed |
| EP-0098629-A1 | Anti-coagulants of the 4-hydroxycoumarin type, the preparation thereof, and rodenticidal compositions (baits) comprising such anti-coagulants | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-01-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163943-A1 | METHODS FOR TREATING DRAVET SYNDROME | CACNA1G, CACNB2, CACNA1H | ANPEP 1649/4885PLAU 1521/4885CYP1A2 4235/4885 |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CACNA1G, CACNA1I, CACNA1H | ANPEP 3130/4885PLAU 3126/4885CYP1A2 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.